Should physicians give tPA to patients with acute ischemic stroke?: Against: And just what is the emperor of stroke wearing?

Western Journal of Medicine

Volumn 173, Issue 3, 2000, Pages 149-150

  Hoffman, J R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIAGNOSTIC ERROR; DRUG EFFICACY; EMERGENCY MEDICINE; FIBRINOLYTIC THERAPY; HUMAN; MORTALITY; PARALYSIS; PHYSICIAN; RISK BENEFIT ANALYSIS; SHORT SURVEY;

BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; RECOVERY OF FUNCTION; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0033815960     PISSN: 00930415     EISSN: None     Source Type: Journal    
DOI: 10.1136/ewjm.173.3.149     Document Type: Short Survey

References (12)

1. Tissue plasminogen activator for acute ischemic stroke
2. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study
3. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke
4. Thrombolytic therapy with streptokinase in acute ischemic stroke
5. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group
6. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators
7. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: A randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke
8. Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: Simulation model
9. Low-molecular-weight heparin for the treatment of acute ischemic stroke
10. Conditions that mimic stroke in the emergency department: Implications for acute stroke trials
11. Cranial computed tomography interpretation in acute stroke: Physician accuracy in determining eligibility for thrombolytic therapy
12. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience